- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06457230
Paired-pulse rTMS Treatment for Methamphetamine Use Disorder Based on the mPFC-Cerebellum
Exploration of the Intervention Mechanism and Efficacy of Paired-pulse rTMS Treatment for Methamphetamine Use Disorder Based on the mPFC-Cerebellum
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Numerous studies have shown that impaired mPFC-cerebellar functional connectivity leads to impaired social preferences and behavioural flexibility and more persistent drug use in addicts. Cerebellar and mPFC paired-pulse rTMS interventions may enhance functional connectivity, effectively modulate cerebellar-prefrontal loops, reduce craving, improve cognitive flexibility, and reduce relapse risk. The aim of this project is to investigate the mechanism and efficacy of a novel paired-pulse rTMS intervention targeting the mPFC-cerebellar circuit in patients with methamphetamine use disorder, in order to develop innovative physiotherapeutic interventions and to optimize treatment and clinical management for individuals with addiction.
Prior to initiating the intervention, it was essential to determine the optimal inter-stimulus interval (ISI) for the cerebellar-mPFC paired associative stimulation. Therefore, a mechanistic study was conducted from December 2024 to June 2025 at the Chengdu Drug Rehabilitation Center in Sichuan Province before the interventional trial commenced. A mixed design was employed, contrasting single-pulse mPFC stimulation with cerebellum→mPFC cortico-cortical paired associative stimulation (ccPAS) at inter-stimulus intervals of 6 ms and 45 ms. The results revealed that individuals with methamphetamine use disorder exhibited aberrant cerebellar-mPFC circuit connectivity compared to healthy controls. Importantly, cerebellar-mPFC ccPAS with a 6-ms ISI was found to specifically modulate this inter-regional circuit dysfunction.
Therefore, based on the identified 6-ms cerebellar-mPFC stimulation interval, the current interventional study continues to implement a long-term, dual-coil combined stimulation protocol to further evaluate and establish its therapeutic efficacy.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Min Zhao, PhD
- Phone Number: 64387250
- Email: drminzhao@gmail.com
Study Contact Backup
- Name: 64387250 Zhao, PhD
- Phone Number: 64387250
- Email: drminzhao@gmail.com
Study Locations
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200000
- Recruiting
- Min Zhao, PhD
-
Contact:
- Min Zhao, PhD
- Phone Number: 64387250
- Email: drminzhao@gmail.com
-
Contact:
- Min Zhao, PhD
- Phone Number: 18017311005
- Email: drminzhao@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria
- Primary substance of abuse is methamphetamine.
- Meets the DSM-5 diagnostic criteria for severe methamphetamine use disorder (≥6 symptoms present within the past year).
- Age: 18-60 years.
- Education level of primary school or above, with the ability to comprehend questionnaires and behavioral tasks.
- Normal vision and hearing; right-handed.
- No prior participation in any TMS-related intervention therapy.
Exclusion Criteria
- Presence of any metallic implants (e.g., dental prostheses, orthodontic braces, bone fixation plates, aneurysm clips, intrauterine devices) or implanted medical devices such as cardiac pacemakers or neurostimulators.
- Chronic or severe somatic diseases (e.g., cardiac conditions, uncontrolled hypertension, physical disabilities).
- Comorbid psychiatric disorders (e.g., schizophrenia, depressive disorders, anxiety disorders).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Sham Comparator: Sham Cerebellar Stimulation + Sham mPFC Stimulation Group
This is the sham stimulation group.
The coil will be placed vertically over the cerebellar and mPFC brain regions, allowing participants to perceive the coil's vibration and sound without receiving effective intervention.
All other stimulation parameters are identical to those in the active intervention group.
|
The coil will be placed vertically over the cerebellar and mPFC brain regions, allowing participants to perceive the coil's vibration and sound without receiving effective intervention.
All other stimulation parameters are identical to those in the active intervention group.
|
|
Experimental: Cerebellar-mPFC Dual-Coil Paired-Pulse TMS Intervention Group
The stimulation protocol involved delivering a pulse to the cerebellum first, followed by a pulse to the mPFC after a 6ms inter-stimulus interval (ISI).
This 6ms interval was determined based on findings from our prior mechanistic study.
|
The protocol consisted of 180 pulse trains.
Each train contained 5 pulse pairs delivered over 1 second, resulting in a stimulation frequency of 5 Hz.
Within each pulse pair, the cerebellum was stimulated first, followed by the mPFC after a 6-ms inter-stimulus interval (ISI).
In total, 900 pulse pairs were administered, and a complete intervention session lasted 11 minutes and 57 seconds.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
cognitive flexibility
Time Frame: Probabilistic reversal learning task: baseline, post-intervention, and at a follow-up session one weeks later; Volatile reversal learning task and Wisconsin Card Sorting Test: baseline and post-intervention; The CFI scale: baseline.
|
Based on tasks and scales assessing cognitive flexibility, including: 1.Probabilistic reversal learning task (The matching of symbols and pictures was reversed without informing the subjects and their cognitive flexibility in the reversed condition was assessed); 2.Volatile reversal learning task (participants were presented with two stimuli associated with their potential feedback magnitude.
They were instructed to choose one of the two stimuli to receive feedback, but only one stimulus would result in feedback.
); 3.The Wisconsin Card Sorting Test (WCST) (a classic neuropsychological task where participants match response cards to four key cards based on hidden sorting rules (color, shape, or number).
They receive "right" or "wrong" feedback after each match and must deduce the current rule, which changes without warning after several consecutive correct matches.); 4. The Cognitive Flexibility Inventory (CFI) scale is a 20-item self-report measure.
|
Probabilistic reversal learning task: baseline, post-intervention, and at a follow-up session one weeks later; Volatile reversal learning task and Wisconsin Card Sorting Test: baseline and post-intervention; The CFI scale: baseline.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Craving
Time Frame: before the intervention (baseline), immediately after the intervention (post-intervention), and at a follow-up session one weeks later.
|
1、The intensity of psychological craving in MA dependents was assessed using the Visual Analogue Scale (VAS), where individuals rated their cravings on a scale from 0 to 100, with higher scores indicating greater levels of craving.
2、Desires for drug questionnaire (DDQ) consists of 13 items designed to assess an individual's current thoughts and preoccupations related to drug use.
3、Obsessive Compulsive Drug Use Scale (OCDUS)consists of 13 items designed to assess an individual's current thoughts and preoccupations related to drug use.
|
before the intervention (baseline), immediately after the intervention (post-intervention), and at a follow-up session one weeks later.
|
|
Electroencephalographic (EEG) Electrophysiological Results
Time Frame: before the intervention (baseline), immediately after the intervention (post-intervention), and at a follow-up session one weeks later.
|
This includes analyses of TMS-EEG, resting-state EEG, and task-state EEG data across temporal, frequency, and time-frequency domains.
|
before the intervention (baseline), immediately after the intervention (post-intervention), and at a follow-up session one weeks later.
|
|
response inhibition
Time Frame: SST task: baseline, post-intervention, and at a follow-up session one weeks later; BIS-11 scale: baseline.
|
The Stop-Signal Task (SST) is a seminal experimental paradigm in cognitive psychology and neuroscience designed to objectively measure an individual's response inhibition-the ability to actively suppress a prepotent or already-initiated motor response.
To gain a more comprehensive understanding of an individual's inhibitory control, it is highly informative to complement this with a trait-based, self-reported measure of impulsivity.
The Barratt Impulsiveness Scale, Version 11 (BIS-11) serves this purpose.
The BIS-11 is a widely validated questionnaire that assesses stable, cross-situational personality traits related to impulsivity across three core dimensions: Attentional Impulsiveness (inability to focus attention), Motor Impulsiveness (tendency to act without thinking), and Non-Planning Impulsiveness (lack of forethought).
|
SST task: baseline, post-intervention, and at a follow-up session one weeks later; BIS-11 scale: baseline.
|
|
Depression
Time Frame: before the intervention (baseline), immediately after the intervention (post-intervention), and at a follow-up session one weeks later.
|
The reduction rate of Beck Depression Inventory (BDI) scores was calculated from baseline to post-intervention and follow-up assessments to quantify the decrease in depressive symptom severity.
|
before the intervention (baseline), immediately after the intervention (post-intervention), and at a follow-up session one weeks later.
|
|
Anxiety
Time Frame: before the intervention (baseline), immediately after the intervention (post-intervention), and at a follow-up session one weeks later.
|
The reduction rate in the Beck Anxiety Inventory (BAI) scores was calculated from baseline to post-intervention and follow-up assessments to quantify the decrease in anxiety symptom severity.
|
before the intervention (baseline), immediately after the intervention (post-intervention), and at a follow-up session one weeks later.
|
|
stress levels
Time Frame: before the intervention (baseline), immediately after the intervention (post-intervention), and at a follow-up session one weeks later.
|
The reduction rate of Perceived Stress Scale (PSS) scores was calculated from baseline to post-intervention and follow-up assessments to quantify the decrease in perceived stress levels.
|
before the intervention (baseline), immediately after the intervention (post-intervention), and at a follow-up session one weeks later.
|
|
sleep quality
Time Frame: before the intervention (baseline), immediately after the intervention (post-intervention), and at a follow-up session one weeks later.
|
The reduction rate of Pittsburgh Sleep Quality Index (PSQI) global scores was calculated from baseline to post-intervention and follow-up assessments to quantify the improvement in sleep quality.
|
before the intervention (baseline), immediately after the intervention (post-intervention), and at a follow-up session one weeks later.
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Min Zhao, PhD, Shanghai Mental Health Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- MZhao-015
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Methamphetamine Use Disorder
-
Elazığ Mental Health and Diseases HospitalRecruitingMethamphetamine Use Disorder | Methamphetamine Induced PsychosisTurkey (Türkiye)
-
Yale UniversityCollege on Problems of Drug DependenceEnrolling by invitationMethamphetamine Use Disorder | Cocaine Use Disorder | Stimulant Use DisorderUnited States
-
William StoopsNational Institute on Drug Abuse (NIDA)RecruitingMethamphetamine Use DisorderUnited States
-
Icahn School of Medicine at Mount SinaiNational Institute on Drug Abuse (NIDA)Recruiting
-
William StoopsNational Institute on Drug Abuse (NIDA)Recruiting
-
Hanoi Medical UniversityNational Institute on Drug Abuse (NIDA)Active, not recruitingMethamphetamine Use DisorderVietnam
-
Turning PointMonash University; Eastern Health; Deakin UniversityCompletedMethamphetamine Use DisorderAustralia
-
University of California, Los AngelesNational Institute on Drug Abuse (NIDA)Terminated
-
The University of Texas Health Science Center,...RecruitingMethamphetamine Use DisorderUnited States
-
University of NebraskaCompleted
Clinical Trials on Sham Intervention Group
-
University of OxfordOxford Brookes UniversityRecruitingOverweight/Obesity, AdolescentUnited Kingdom
-
United States Naval Medical Center, San DiegoThe Defense and Veterans Brain Injury CenterCompletedBrain Injuries | Brain Injuries, Traumatic | Brain Concussion | Mild Cognitive Impairment | Memory Impairment | Mild Traumatic Brain Injury | Attention Impaired | Neurocognitive Dysfunction | Brain Trauma | Attention Concentration DifficultyUnited States
-
University of Castilla-La ManchaMinistry of Science and Innovation, Spain; Asociación Parkinson Toledo (CAP...CompletedMotor Activity | Parkinson's Disease and Parkinsonism | Nerve BlockSpain
-
Duke UniversityNational Institute of Nursing Research (NINR); National Institutes of Health...CompletedChronic Kidney Diseases | Diabetes Mellitus, Type 1 | Systemic Lupus Erythematosus | Inflammatory Bowel Diseases | Cystic Fibrosis | Sickle Cell Disease | Stem Cell Transplant | Childhood Cancer | Organ TransplantUnited States
-
University of Castilla-La ManchaHospital Nacional de Parapléjicos de ToledoCompletedNeuropathic Pain | Spinal Cord Injuries (SCI)Spain
-
Hospital de Clinicas de Porto AlegreCompletedFeeding Behavior | Infant, PrematureBrazil
-
Jade Carvalho Da SilvaSantos Dumont InstituteNot yet recruitingLong COVID | Brain Fog | Post-Acute COVID-19 SyndromeBrazil
-
Finis Terrae UniversityNot yet recruitingPostoperative Pain | Respiratory ComplicationChile
-
Capital Medical University307 Hospital of PLAUnknownStroke | Children | Moyamoya Disease | TIAChina